Global protein-expression profiling for reclassification of malignant fibrous histiocytoma

Kazutaka Kikuta, Hideo Morioka, Akira Kawai, Tadashi Kondo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

According to the newest World Health Organization (WHO) classification for soft tissue tumors in 2013, malignant fibrous histiocytoma (MFH) has been gone. Most sarcomas called MFH were reclassified to be high-grade pleomorphic forms of leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and other sarcomas by recent molecular technologies. However, about 10% to 15% of sarcomas called MFH before, still cannot be given a precise classification, and these are now called undifferentiated pleomorphic sarcoma or are still called MFH. Further molecular approaches including proteomic approaches are imperative to classify these unclassified sarcomas for improving clinical outcomes of the patients with soft tissue sarcomas. This article is part of a Special Issue entitled: Medical Proteomics.

Original languageEnglish
Pages (from-to)696-701
Number of pages6
JournalBiochimica et Biophysica Acta - Proteins and Proteomics
Volume1854
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

Malignant Fibrous Histiocytoma
Sarcoma
Tissue
Tumors
Proteins
Health
Proteomics
Liposarcoma
Leiomyosarcoma
Rhabdomyosarcoma
Technology
Neoplasms

Keywords

  • Classification
  • MFH
  • Proteomics
  • STS

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Analytical Chemistry
  • Molecular Biology

Cite this

Global protein-expression profiling for reclassification of malignant fibrous histiocytoma. / Kikuta, Kazutaka; Morioka, Hideo; Kawai, Akira; Kondo, Tadashi.

In: Biochimica et Biophysica Acta - Proteins and Proteomics, Vol. 1854, No. 6, 01.06.2015, p. 696-701.

Research output: Contribution to journalArticle

Kikuta, Kazutaka ; Morioka, Hideo ; Kawai, Akira ; Kondo, Tadashi. / Global protein-expression profiling for reclassification of malignant fibrous histiocytoma. In: Biochimica et Biophysica Acta - Proteins and Proteomics. 2015 ; Vol. 1854, No. 6. pp. 696-701.
@article{e8206d8dd0814969ad3f91efc9935198,
title = "Global protein-expression profiling for reclassification of malignant fibrous histiocytoma",
abstract = "According to the newest World Health Organization (WHO) classification for soft tissue tumors in 2013, malignant fibrous histiocytoma (MFH) has been gone. Most sarcomas called MFH were reclassified to be high-grade pleomorphic forms of leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and other sarcomas by recent molecular technologies. However, about 10{\%} to 15{\%} of sarcomas called MFH before, still cannot be given a precise classification, and these are now called undifferentiated pleomorphic sarcoma or are still called MFH. Further molecular approaches including proteomic approaches are imperative to classify these unclassified sarcomas for improving clinical outcomes of the patients with soft tissue sarcomas. This article is part of a Special Issue entitled: Medical Proteomics.",
keywords = "Classification, MFH, Proteomics, STS",
author = "Kazutaka Kikuta and Hideo Morioka and Akira Kawai and Tadashi Kondo",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.bbapap.2014.08.012",
language = "English",
volume = "1854",
pages = "696--701",
journal = "Biochimica et Biophysica Acta - Proteins and Proteomics",
issn = "1570-9639",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Global protein-expression profiling for reclassification of malignant fibrous histiocytoma

AU - Kikuta, Kazutaka

AU - Morioka, Hideo

AU - Kawai, Akira

AU - Kondo, Tadashi

PY - 2015/6/1

Y1 - 2015/6/1

N2 - According to the newest World Health Organization (WHO) classification for soft tissue tumors in 2013, malignant fibrous histiocytoma (MFH) has been gone. Most sarcomas called MFH were reclassified to be high-grade pleomorphic forms of leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and other sarcomas by recent molecular technologies. However, about 10% to 15% of sarcomas called MFH before, still cannot be given a precise classification, and these are now called undifferentiated pleomorphic sarcoma or are still called MFH. Further molecular approaches including proteomic approaches are imperative to classify these unclassified sarcomas for improving clinical outcomes of the patients with soft tissue sarcomas. This article is part of a Special Issue entitled: Medical Proteomics.

AB - According to the newest World Health Organization (WHO) classification for soft tissue tumors in 2013, malignant fibrous histiocytoma (MFH) has been gone. Most sarcomas called MFH were reclassified to be high-grade pleomorphic forms of leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and other sarcomas by recent molecular technologies. However, about 10% to 15% of sarcomas called MFH before, still cannot be given a precise classification, and these are now called undifferentiated pleomorphic sarcoma or are still called MFH. Further molecular approaches including proteomic approaches are imperative to classify these unclassified sarcomas for improving clinical outcomes of the patients with soft tissue sarcomas. This article is part of a Special Issue entitled: Medical Proteomics.

KW - Classification

KW - MFH

KW - Proteomics

KW - STS

UR - http://www.scopus.com/inward/record.url?scp=84939954855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939954855&partnerID=8YFLogxK

U2 - 10.1016/j.bbapap.2014.08.012

DO - 10.1016/j.bbapap.2014.08.012

M3 - Article

C2 - 25173742

AN - SCOPUS:84939954855

VL - 1854

SP - 696

EP - 701

JO - Biochimica et Biophysica Acta - Proteins and Proteomics

JF - Biochimica et Biophysica Acta - Proteins and Proteomics

SN - 1570-9639

IS - 6

ER -